Oxaliplatin liposomal - Mebiopharm

Drug Profile

Oxaliplatin liposomal - Mebiopharm

Alternative Names: L-OHP; MBP-426

Latest Information Update: 28 Oct 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mebiopharm
  • Class Antineoplastics; Platinum complexes; Small molecules
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenocarcinoma

Most Recent Events

  • 21 Oct 2016 Phase-II clinical trials in Adenocarcinoma (of gastric and gastroesophageal junction) (Combination therapy, Second-line therapy) in USA (IV) (Mebiopharm pipeline, October 2016)
  • 07 Jun 2013 Biomarkers information updated
  • 01 Feb 2011 Mebiopharm completes enrolment in its phase I/II trial in Adenocarcinoma in USA (NCT00964080)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top